FY2026 · ended Jun 30, 2026 · Revenue $182.59M, -20.1% YoY · Filed Aug 27, 2026
Lifevantage Corp (LFVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $182.6 million and net income of $5.1 million. Free cash flow was $6.7 million. As of Jun 30, 2026 it held $14.9 million in cash and investments and $9.9 million in total debt.
Revenue
$182.59M
-20.1% vs prior year
Net income
$5.07M
-48.3% vs prior year
Operating cash flow
$10.24M
-13.8% vs prior year
Free cash flow
$6.67M
-36.5% vs prior year
EPS
$0.40
-46.7% vs prior year
Dividend per share
$0.18
+12.1% vs prior year
Shares outstanding
12.53M
-1.3% vs prior year
Net cash
$5.05M
FY 2026
Operating margin
3.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFVN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lehi, UT
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 849146
- Former names
- LIFELINE THERAPEUTICS, INC. (until Dec 6, 2006); YAAK RIVER RESOURCES INC (until Sep 28, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $182.6M | $228.5M | $200.2M | $213.4M | $206.4M |
| Operating income | $6.1M | $12.2M | $4.3M | $4.3M | $7.6M |
| Net income | $5.1M | $9.8M | $2.9M | $2.5M | $3.1M |
| Diluted EPS | $0.40 | $0.75 | $0.23 | $0.20 | $0.24 |
| Operating cash flow | $10.2M | $11.9M | $12.2M | $6.8M | $8.0M |
| Free cash flow | $6.7M | $10.5M | $10.0M | $3.8M | $6.4M |
| Total assets | $62.1M | $72.0M | $60.3M | $66.1M | $70.7M |
| Total liabilities | $28.5M | $37.3M | $34.3M | $31.5M | $39.2M |
| Stockholders' equity | $33.6M | $34.6M | $26.0M | $34.6M | $31.5M |
| Cash and investments | $14.9M | $20.2M | $16.9M | $21.6M | $20.2M |
| Total debt | $9.9M | $11.7M | $13.6M | $13.1M | $15.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 5, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-K | Annual report | Aug 27, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 3, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
All 1001 Lifevantage Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.